A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2001
12/27/2001	US20010056116 A prodrug compound capable of facilitating the passage of a drug across the blood brain barrier comprising a fatty acid coupled to a drug to form a prodrug
12/27/2001	US20010056114 Treating an eye condition associated with angiogenesis in a human or animal comprising administering to the patient an angiogenesis inhibiting amount of EM-138 ( a isoindol-2-one substituted by hydroxy-glutamic acid)
12/27/2001	US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12
12/27/2001	US20010056077 Pharmaceutical composition for treatment of duchenne muscular dystrophy
12/27/2001	US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6
12/27/2001	US20010056075 Chimeric polypeptides of serum albumin and uses related thereto
12/27/2001	US20010056073 Revascularizing ischemic tissue or improving vascular flow of ischemic tissue by administering angiogenesis inducing gene encoding angiogenesis growth factor encapsulated in liposomal carrier vehicle into ischemic tissue
12/27/2001	US20010056069 Use of collagen for the treatment of degenerative articular processes
12/27/2001	US20010056068 Such as atherosclerosis, restenosis, hypertension, preeclampsia and/or intrauterine fetal growth retardation, infection, SLE-lupus, anaphylactic reaction, allograft rejection, hormone replacement therapy, Alzheimer's disease
12/27/2001	US20010056067 Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
12/27/2001	US20010056066 Increasing systemic exposure of a therapeutic protein through two administrations, the second higher dosage than the first; binding the immune cell antigen with saturating amount of monoclonal antibody for example; autoimmune diseases
12/27/2001	US20010056064 Determining respiratory quotient(RQ), have patient consume liquid or food containing glucose, administering pulse of insulin at regular time interval until the RQ reaches a specified value; enhances pyruvate dehydrogenase activity
12/27/2001	US20010056063 Method of treating or preventing type 1 diabetes by oral administration of insulin
12/27/2001	US20010056062 As osmotic agents synthetic polypeptides of two to fifteen amino acids long; slow transport across the peritoneum, for prolonged osmotic gradient between dialysate and blood
12/27/2001	US20010056061 Eliminate the Bovine Spongiform Encephalopathy (BSE) risk by synthesizing a thymic peptide; short-chain peptides with a weighted quantity ratio and a pattern of amino acids characteristic of thymus tissue
12/27/2001	US20010055789 Nucleotide sequences for use in the generation of amidated peptides
12/27/2001	US20010055788 Recombinant bacterial phytases and uses thereof
12/27/2001	US20010055782 Enzymatic protein for use in the diagnosis, treatment and prevention of alzheimer's disease and nervous system disorders
12/27/2001	US20010055780 Bacteriophage coupling to enzyme
12/27/2001	US20010055777 Potentiation of the immune response
12/27/2001	US20010055758 Reagents and methods useful for detecting diseases of the prostate
12/27/2001	US20010055756 Internal de novo initiation sites of the HCV NS5B polymerase and use thereof
12/27/2001	US20010055751 PSCA: Prostate stem cell antigen and uses thereof
12/27/2001	US20010055617 Method and preparations for stabilizing biological materials by drying methods without freezing
12/27/2001	US20010055602 Topical applying
12/27/2001	US20010055596 Compositions and methods for therapy and diagnosis of colon cancer
12/27/2001	US20010055594 Inhibiting Tumor Necrosis Factor (TNF)-alpha for treating nerve disorders by administering a TNF-alpha inhibitor selected from specified monoclonal antibodies; herniated discs, pain, nucleus pulposus-induced nerve injury, sciatica
12/27/2001	US20010055592 Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis
12/27/2001	US20010055591 Antithrombin H-helix mutants
12/27/2001	US20010055587 Transplantation of neural cells for the treatment of chronic pain or spasticity
12/27/2001	US20010055585 Frnk proteins in the treatment of tumor cells
12/27/2001	US20010055584 Improved nucleic acids encoding a chimeric glycosyltransferase
12/27/2001	US20010055582 Erythropoietin solution preparation
12/27/2001	CA2814737A1 Transgenic animal model of neurodegenerative disorders
12/27/2001	CA2713965A1 Glycopeptide phosphonate derivatives
12/27/2001	CA2414228A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
12/27/2001	CA2414065A1 Cgi-69 compositions and methods of use
12/27/2001	CA2414046A1 Conserved diaphanous-related formin autoregulatory domain (dad)
12/27/2001	CA2414033A1 Control of metabolism with compositions of the human 2-oxoglutarate carrier
12/27/2001	CA2414028A1 Low oxygen affinity mutant hemoglobins
12/27/2001	CA2414020A1 Methods and compositions for the treatment of peripheral artery disease
12/27/2001	CA2414015A1 Human receptors
12/27/2001	CA2414010A1 Secreted redox proteins
12/27/2001	CA2413986A1 Gp354 nucleic acids and polypeptides
12/27/2001	CA2413974A1 Neuroactive peptides for treatment of hypoxia and related conditions
12/27/2001	CA2413957A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
12/27/2001	CA2413860A1 Regulation of cellproliferation and differentiation using topically applied peptides
12/27/2001	CA2413830A1 Peptide and polypeptide inhibitors of complement c1s
12/27/2001	CA2413754A1 Canine hepatocyte growth factor
12/27/2001	CA2413612A1 Modified construct downstream of the initiation codon for recombinant protein overexpression
12/27/2001	CA2413556A1 Positively-charged peptide nucleic acid analogs with improved properties
12/27/2001	CA2413526A1 Micro-organisms active in the digestive environment
12/27/2001	CA2413502A1 Tumour-cell specific gene expression and its use in cancer therapy
12/27/2001	CA2413468A1 Methods and means for regulation of gene expression
12/27/2001	CA2413454A1 A g-protein coupled receptor
12/27/2001	CA2413328A1 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
12/27/2001	CA2413324A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/27/2001	CA2413253A1 Matrix protein compositions for dentin regeneration
12/27/2001	CA2413252A1 Preventives or remedies for heart failure
12/27/2001	CA2412849A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
12/27/2001	CA2412835A1 Osteoclast secreted chemokine and uses thereof
12/27/2001	CA2412734A1 Renal regulatory elements and methods of use thereof
12/27/2001	CA2412484A1 G-protein coupled receptors
12/27/2001	CA2412219A1 Transgenically produced platelet derived growth factor
12/27/2001	CA2412215A1 Angiogenesis-modulating compositions and uses
12/27/2001	CA2412110A1 Osteolevin gene polymorphisms
12/27/2001	CA2412013A1 Polynucleotides encoding human serine proteases
12/27/2001	CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/27/2001	CA2411971A1 Proteases
12/27/2001	CA2411857A1 Peptides, compositions and methods for the treatment of burkholderia cepacia
12/27/2001	CA2411756A1 Mutation associated with epilepsy
12/27/2001	CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001	CA2410864A1 Compositions comprising net-4 modulations and their use for treating neoplastic disease
12/27/2001	CA2410224A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
12/27/2001	CA2409781A1 Phosphodiesterases
12/27/2001	CA2409778A1 Secreted proteins
12/27/2001	CA2409776A1 G-protein coupled receptors
12/27/2001	CA2407847A1 Transgenic animal model of neurodegenerative disorders
12/27/2001	CA2407788A1 Method for activating peroxisome proliferator activated receptor-.gamma.
12/26/2001	CN1328570A Antagonistic analogs in GH-RH inhibiting IGF-I and -II
12/26/2001	CN1328569A TGF (b) 1 inhibitor peptides
12/26/2001	CN1328568A Peptide derivative
12/26/2001	CN1328567A Mammaglobin, a secreted mammary-specific breast cancer protein
12/26/2001	CN1328470A Chemokine receptor peptide vaccines for treatment and prevention of diabetes
12/26/2001	CN1328469A Use of parvovirus capsid particles in inhibition of cell proliferation and migration
12/26/2001	CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state
12/26/2001	CN1328155A Polypeptide-human topoisomeras I 9.79 and polynucleotide for coding it
12/26/2001	CN1328154A Polypeptide-DNA topoisomerase II-beta (TOP2B)10.34 and polynucleotide for coding it
12/26/2001	CN1328153A Polypeptide-dihydroorotase 10 and polynucleotide for coding it
12/26/2001	CN1328152A Polypeptide-human NRD transferase 10.01 and polynucleotide for coding it
12/26/2001	CN1328151A Polypeptide-proteasome p 40.5 subunit 9.79 and polynucleotide for coding it
12/26/2001	CN1328149A Polypeptide-phosphodiesterase 10.12 and polynucleotide for coding it
12/26/2001	CN1328147A Polypeptide-human phosphatidase 49.06 and polynucleotide for coding it
12/26/2001	CN1328145A Human mannose transferase and its coding sequence
12/26/2001	CN1328142A Polypeptide-dihydropyrrole-5-carboxylate reductase 15 and polynucleotide for coding it
12/26/2001	CN1328141A Polypeptide-isopenicillin N synthase 31 and polynucleotide for coding it
12/26/2001	CN1328140A Polypeptide-citrate synthase 11.77 and polynucleotide for coding it
12/26/2001	CN1328139A Polypeptide-human 6-acetonylacyl tetrahydogen (biologic) pterin synthase (PTPS) 41.03 and polynucleotide for coding it
12/26/2001	CN1328138A Polypeptide-human RNA cyclase 12 and plynucleotide for coding it
12/26/2001	CN1328137A Polypeptide-human ubiquitin desmoenzyme 9.46 and polynucleotide for coding it

1 ... 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 ... 3163